Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study

Salvatrice Mancuso,1 Melania Carlisi,1 Nicola Serra,2,3 Mariasanta Napolitano,1 Simona Raso,3 Ugo Consoli,4 Roberto Palazzolo,5 Maria Rosa Lanza Cariccio,6 Sergio Siragusa1 1Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) Department, Universit...

Full description

Bibliographic Details
Main Authors: Mancuso S, Carlisi M, Serra N, Napolitano M, Raso S, Consoli U, Palazzolo R, Lanza Cariccio MR, Siragusa S
Format: Article
Language:English
Published: Dove Medical Press 2020-08-01
Series:Journal of Blood Medicine
Subjects:
Online Access:https://www.dovepress.com/clinical-phenotype-and-response-to-different-lines-of-therapy-in-elder-peer-reviewed-article-JBM
_version_ 1818363098283638784
author Mancuso S
Carlisi M
Serra N
Napolitano M
Raso S
Consoli U
Palazzolo R
Lanza Cariccio MR
Siragusa S
author_facet Mancuso S
Carlisi M
Serra N
Napolitano M
Raso S
Consoli U
Palazzolo R
Lanza Cariccio MR
Siragusa S
author_sort Mancuso S
collection DOAJ
description Salvatrice Mancuso,1 Melania Carlisi,1 Nicola Serra,2,3 Mariasanta Napolitano,1 Simona Raso,3 Ugo Consoli,4 Roberto Palazzolo,5 Maria Rosa Lanza Cariccio,6 Sergio Siragusa1 1Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) Department, University of Palermo, Palermo, Italy; 2Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples, Italy; 3Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy; 4UOC Ematologia ARNAS Garibaldi, Catania, Italy; 5UOS Ematologia, Asst Valtellina e Alto Lario, Sondrio, Italy; 6Dipartimento Oncologico, La Maddalena, UOC Di Oncoematologia e TMO, Palermo, ItalyCorrespondence: Melania CarlisiHealth Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) Department, University of Palermo, 129 Via del Vespro, Palermo 90127, ItalyTel +39 091-655-4504Fax +39 0916554502Email melania.carlisi@unipa.itPurpose: Insufficient knowledge of primary immune thrombocytopenia purpura (ITP) in the elderly, together with a lack of clinical trial data, has resulted in wide variation in treatments. Here, we present a study focused on clinical characteristics of ITP in older subjects at diagnosis integrated with the subsequent course of the disease and treatment history.Methods: In a retrospective monoinstitutional study, we evaluated > 65-year-old patients with primary ITP. Clinical characteristics at the time of diagnosis were described and analyzed. We aimed to delineate whether subsequent lines of therapy influenced the number of relapses. In addition to initial regimens, we reported subsequent treatments and the impact on relapse trends.Results: A total of 50 patients (56% males, mean age 78 years) were included. With regard to clinical variables at diagnosis, statistical significance was found for Eastern Cooperative Oncology Group performance status 1 (46% of patients, p< 0.0001), presence of three comorbidities (36% of patients, p< 0.0001), World Health Organization grade 0 bleeding (46%, p=0.0001), and World Health Organization grade 1 bleeding (42%, p=0.0009). For bleeding sites, the most frequent were skin or mucosa (40%, p=0.0477). A decrease in platelet count was correlated with moderate or severe bleeding (ρ=− 0.52, p=0.0001) and viscera or skin/mucosa + viscera site (ρ=− 0.50, p=0.0002). Finally, a decreasing number of patients required treatment from first-line therapy to sixth (p< 0.0001). Relapse was most frequent before second-line therapy (54%, p< 0.0001) and less frequent before fivth and sixth (4%, p=0.0072; 2%, p=0.0027).Conclusion: ITP in older age poses considerable challenges, so specific management strategies should be considered to optimize outcomes. Our findings provide evidence of an inverse relationship between lines of therapy and timing of relapses. This study does not exclude the possibility that agents used after first-line therapy may have an impact on the response and modify the unfavorable course of ITP.Keywords: primary immune thrombocytopenia, ITP, immunogeriatrics, Tpo-receptor agonist, ITP treatment, aging
first_indexed 2024-12-13T21:43:04Z
format Article
id doaj.art-60623980af1b4c09be8a5972bf626fbc
institution Directory Open Access Journal
issn 1179-2736
language English
last_indexed 2024-12-13T21:43:04Z
publishDate 2020-08-01
publisher Dove Medical Press
record_format Article
series Journal of Blood Medicine
spelling doaj.art-60623980af1b4c09be8a5972bf626fbc2022-12-21T23:30:29ZengDove Medical PressJournal of Blood Medicine1179-27362020-08-01Volume 1125125855943Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective StudyMancuso SCarlisi MSerra NNapolitano MRaso SConsoli UPalazzolo RLanza Cariccio MRSiragusa SSalvatrice Mancuso,1 Melania Carlisi,1 Nicola Serra,2,3 Mariasanta Napolitano,1 Simona Raso,3 Ugo Consoli,4 Roberto Palazzolo,5 Maria Rosa Lanza Cariccio,6 Sergio Siragusa1 1Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) Department, University of Palermo, Palermo, Italy; 2Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples, Italy; 3Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy; 4UOC Ematologia ARNAS Garibaldi, Catania, Italy; 5UOS Ematologia, Asst Valtellina e Alto Lario, Sondrio, Italy; 6Dipartimento Oncologico, La Maddalena, UOC Di Oncoematologia e TMO, Palermo, ItalyCorrespondence: Melania CarlisiHealth Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) Department, University of Palermo, 129 Via del Vespro, Palermo 90127, ItalyTel +39 091-655-4504Fax +39 0916554502Email melania.carlisi@unipa.itPurpose: Insufficient knowledge of primary immune thrombocytopenia purpura (ITP) in the elderly, together with a lack of clinical trial data, has resulted in wide variation in treatments. Here, we present a study focused on clinical characteristics of ITP in older subjects at diagnosis integrated with the subsequent course of the disease and treatment history.Methods: In a retrospective monoinstitutional study, we evaluated > 65-year-old patients with primary ITP. Clinical characteristics at the time of diagnosis were described and analyzed. We aimed to delineate whether subsequent lines of therapy influenced the number of relapses. In addition to initial regimens, we reported subsequent treatments and the impact on relapse trends.Results: A total of 50 patients (56% males, mean age 78 years) were included. With regard to clinical variables at diagnosis, statistical significance was found for Eastern Cooperative Oncology Group performance status 1 (46% of patients, p< 0.0001), presence of three comorbidities (36% of patients, p< 0.0001), World Health Organization grade 0 bleeding (46%, p=0.0001), and World Health Organization grade 1 bleeding (42%, p=0.0009). For bleeding sites, the most frequent were skin or mucosa (40%, p=0.0477). A decrease in platelet count was correlated with moderate or severe bleeding (ρ=− 0.52, p=0.0001) and viscera or skin/mucosa + viscera site (ρ=− 0.50, p=0.0002). Finally, a decreasing number of patients required treatment from first-line therapy to sixth (p< 0.0001). Relapse was most frequent before second-line therapy (54%, p< 0.0001) and less frequent before fivth and sixth (4%, p=0.0072; 2%, p=0.0027).Conclusion: ITP in older age poses considerable challenges, so specific management strategies should be considered to optimize outcomes. Our findings provide evidence of an inverse relationship between lines of therapy and timing of relapses. This study does not exclude the possibility that agents used after first-line therapy may have an impact on the response and modify the unfavorable course of ITP.Keywords: primary immune thrombocytopenia, ITP, immunogeriatrics, Tpo-receptor agonist, ITP treatment, aginghttps://www.dovepress.com/clinical-phenotype-and-response-to-different-lines-of-therapy-in-elder-peer-reviewed-article-JBMprimary immune thrombocytopenia (itp)immuno-geriatricstpo-receptor agonistitp treatmentaging.
spellingShingle Mancuso S
Carlisi M
Serra N
Napolitano M
Raso S
Consoli U
Palazzolo R
Lanza Cariccio MR
Siragusa S
Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study
Journal of Blood Medicine
primary immune thrombocytopenia (itp)
immuno-geriatrics
tpo-receptor agonist
itp treatment
aging.
title Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study
title_full Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study
title_fullStr Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study
title_full_unstemmed Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study
title_short Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study
title_sort clinical phenotype and response to different lines of therapy in elderly with immune thrombocytopenia a retrospective study
topic primary immune thrombocytopenia (itp)
immuno-geriatrics
tpo-receptor agonist
itp treatment
aging.
url https://www.dovepress.com/clinical-phenotype-and-response-to-different-lines-of-therapy-in-elder-peer-reviewed-article-JBM
work_keys_str_mv AT mancusos clinicalphenotypeandresponsetodifferentlinesoftherapyinelderlywithimmunethrombocytopeniaaretrospectivestudy
AT carlisim clinicalphenotypeandresponsetodifferentlinesoftherapyinelderlywithimmunethrombocytopeniaaretrospectivestudy
AT serran clinicalphenotypeandresponsetodifferentlinesoftherapyinelderlywithimmunethrombocytopeniaaretrospectivestudy
AT napolitanom clinicalphenotypeandresponsetodifferentlinesoftherapyinelderlywithimmunethrombocytopeniaaretrospectivestudy
AT rasos clinicalphenotypeandresponsetodifferentlinesoftherapyinelderlywithimmunethrombocytopeniaaretrospectivestudy
AT consoliu clinicalphenotypeandresponsetodifferentlinesoftherapyinelderlywithimmunethrombocytopeniaaretrospectivestudy
AT palazzolor clinicalphenotypeandresponsetodifferentlinesoftherapyinelderlywithimmunethrombocytopeniaaretrospectivestudy
AT lanzacaricciomr clinicalphenotypeandresponsetodifferentlinesoftherapyinelderlywithimmunethrombocytopeniaaretrospectivestudy
AT siragusas clinicalphenotypeandresponsetodifferentlinesoftherapyinelderlywithimmunethrombocytopeniaaretrospectivestudy